Radiation Oncology

ESMO 2024

Questions discussed in this category

What are your top takeaways in Breast Cancer from ESMO 2024?

4 Answers available

With the presentation of HypoG-01 phase III UNICANCER trial at ESMO 2024, should hypofractionated radiotherapy be the standard across the board for breast cancer?

1 Answer available

Papers discussed in this category

N. Engl. J. Med., 1997-10-02

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.

N. Engl. J. Med., 2010-02-11

Long-term results of hypofractionated radiation therapy for breast cancer.

Eur. J. Cancer, 2015-03-01

Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial.

Lancet, 2019 Dec 14

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.

The New England journal of medicine, 2024 Sep 15

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Nature medicine, 2024 Sep 13

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Oct 21

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.

The New England journal of medicine, 2024 Sep 15

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

Related Topics in Radiation Oncology